Site Search

Search
Showing 1 - 6 of 6 results
About the CF Foundation | Drug Pipeline | Antibiotics
FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade

CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality

Press Release |
| 4 min read
Antibiotics | Advocacy
CF Foundation Affirms Support of the Introduction of the PASTEUR Act

Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.

Press Release |
| 2 min read
Research | Antibiotics | About the CF Foundation
CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonas

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.

Press Release |
| 3 min read